author-photo

Robert C. Kane

Center for Drug Evaluation and Research

33

Papers

2597

Citations

Citation Trend

Filter By

Papers (23) Sort By

Journal Conference Others

FDA Approval: Blinatumomab

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (151)
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products

2015 JAMA
Show All
- Source
- Cite
- Save
Citations (125)
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (78)
FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (94)
Poor ESA Responders As Defined By Week 4 Hemoglobin Response Have Greater ESA Dosing but Worse Cardiovascular Outcomes in Patients with Anemia of Chronic Kidney Disease (CKD) Not on Dialysis

2014 Blood
Show All
- Source
- Cite
- Save
Citations (0)
U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

2014 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (32)
U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

2014 Oncologist
Show All
- Source
- Cite
- Save
Citations (53)
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

2012 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (157)
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia

2010 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

2009 Oncologist
Show All
- Source
- Cite
- Save
Citations (164)